These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 7768011)

  • 1. Accumulation of atherogenic remnants and lipoprotein(a) in the nephrotic syndrome: relation to remission of proteinuria.
    Joven J; Simó JM; Vilella E; Camps J; Espinel E; Villabona C
    Clin Chem; 1995 Jun; 41(6 Pt 1):908-13. PubMed ID: 7768011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated lipoprotein (a) levels in primary nephrotic syndrome.
    Faucher C; Doucet C; Baumelou A; Chapman J; Jacobs C; Thillet J
    Am J Kidney Dis; 1993 Dec; 22(6):808-13. PubMed ID: 8250027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-density lipoprotein metabolism and its association to plasma lipoprotein(a) in the nephrotic syndrome.
    Stenvinkel P; Berglund L; Ericsson S; Alvestrand A; Angelin B; Eriksson M
    Eur J Clin Invest; 1997 Feb; 27(2):169-77. PubMed ID: 9061312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II antagonism improves the lipoprotein profile in patients with nephrotic syndrome.
    de Zeeuw D; Gansevoort RT; Dullaart RP; de Jong PE
    J Hypertens Suppl; 1995 Jul; 13(1):S53-8. PubMed ID: 18800457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipoprotein profiles in a heterogeneous group of patients with nephrotic syndrome.
    Michaeli J; Bar-On H; Shafrir E
    Isr J Med Sci; 1981 Nov; 17(11):1001-8. PubMed ID: 7319786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipoprotein(a) in patients with the nephrotic syndrome: influence of immunosuppression and proteinuria.
    Wanner C; Bartens W; Nauck M; Zäuner I; Greiber S; Schollmeyer P
    Miner Electrolyte Metab; 1996; 22(1-3):26-30. PubMed ID: 8676820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of hypoalbuminemia in the generation of nephrotic hyperlipidemia.
    Joven J; Espinel E; Simó JM; Vilella E; Camps J; Oliver A
    Atherosclerosis; 1996 Oct; 126(2):243-52. PubMed ID: 8902150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome.
    Wanner C; Rader D; Bartens W; Krämer J; Brewer HB; Schollmeyer P; Wieland H
    Ann Intern Med; 1993 Aug; 119(4):263-9. PubMed ID: 8328733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipoprotein(a) levels in relation to albumin concentration in childhood nephrotic syndrome.
    Noto D; Barbagallo CM; Cascio AL; Cefalù AB; Cavera G; Caldarella R; Marino G; Travali S; Cutaia I; Maringhini S; Notarbartolo A; Averna M
    Kidney Int; 1999 Jun; 55(6):2433-9. PubMed ID: 10354292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis.
    Attman PO; Samuelsson OG; Moberly J; Johansson AC; Ljungman S; Weiss LG; Knight-Gibson C; Alaupovic P
    Kidney Int; 1999 Apr; 55(4):1536-42. PubMed ID: 10201020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences.
    Vaziri ND
    Kidney Int; 2016 Jul; 90(1):41-52. PubMed ID: 27165836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The atherogenic lipoprotein phenotype: small dense LDL and lipoprotein remnants in nephrotic range proteinuria.
    Deighan CJ; Caslake MJ; McConnell M; Boulton-Jones JM; Packard CJ
    Atherosclerosis; 2001 Jul; 157(1):211-20. PubMed ID: 11427223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A study of the clinical significance of lipoprotein (a) in nephrotic syndrome.
    Takegoshi T; Kitoh C; Haba T; Hirai J; Wakasugi T; Saga T; Yamazaki Y; Mabuchi H
    Jpn J Med; 1991; 30(1):21-5. PubMed ID: 1830908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of apoprotein epsilon 2 homozygosity on nephrotic hyperlipidemia.
    Joven J; Vilella E
    Clin Nephrol; 1997 Sep; 48(3):141-5. PubMed ID: 9342484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lp(a) lipoprotein concentration in serum of patients with heavy proteinuria of different origin.
    Karádi I; Romics L; Pálos G; Domán J; Kaszás I; Hesz A; Kostner GM
    Clin Chem; 1989 Oct; 35(10):2121-3. PubMed ID: 2529062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in serum apolipoprotein and lipoprotein profile induced by chronic alcohol consumption and withdrawal: determinant effect on heart disease?
    Lecomte E; Herbeth B; Paille F; Steinmetz J; Artur Y; Siest G
    Clin Chem; 1996 Oct; 42(10):1666-75. PubMed ID: 8855152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum remnant lipoprotein levels in nephrotic syndrome.
    Kinoshita H; Uezono S; Fukudome K; Yokota N; Hisanaga S; Fujimoto S; Eto T
    Clin Nephrol; 2001 Mar; 55(3):263-4. PubMed ID: 11316252
    [No Abstract]   [Full Text] [Related]  

  • 18. Lipoprotein(a) serum levels and apolipoprotein(a) phenotypes in children with chronic renal disease.
    Querfeld U; Lang M; Friedrich JB; Kohl B; Fiehn W; Schärer K
    Pediatr Res; 1993 Dec; 34(6):772-6. PubMed ID: 8108191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipopheresis in the nephrotic syndrome.
    Brunton C; Varghese Z; Moorhead JF
    Kidney Int Suppl; 1999 Jul; 71():S6-9. PubMed ID: 10412726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Symptomatic antiproteinuric treatment decreases serum lipoprotein (a) concentration in patients with glomerular proteinuria.
    Gansevoort RT; Heeg JE; Dikkeschei FD; de Zeeuw D; de Jong PE; Dullaart RP
    Nephrol Dial Transplant; 1994; 9(3):244-50. PubMed ID: 8052429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.